UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects

Alimentary pharmacology & therapeutics, 2003-09, Vol.18 (5), p.533-541

2003

Volltextzugriff (PDF)

Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects

Journal of clinical pharmacology, 2005-10, Vol.45 (10), p.1172-1178

2005

Volltextzugriff (PDF)

Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration

International journal of clinical pharmacology and therapeutics, 2010-02, Vol.48 (2), p.103-108

2010

Volltextzugriff (PDF)

Clinical pharmacology of lumiracoxib : A selective cyclo-oxygenase-2 inhibitor

Clinical pharmacokinetics, 2005-01, Vol.44 (12), p.1247-1266

2005

Volltextzugriff (PDF)

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Arthritis research & therapy, 2008-01, Vol.10 (3), p.R67-R67, Article R67

2008

Volltextzugriff (PDF)

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor

Pharmacological research, 2004-08, Vol.50 (2), p.181-186

2004

Volltextzugriff (PDF)

Increased interleukin-1 beta (IL-1β) concentration in gingival tissue from periodontitis patients

Journal of periodontal research, 1989-11, Vol.24 (6), p.362-367

1989

Volltextzugriff (PDF)

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

Transplantation, 2002-03, Vol.73 (6), p.920-925

2002

Volltextzugriff (PDF)

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

Drug metabolism and disposition, 2004-05, Vol.32 (5), p.566-571

2004

Volltextzugriff (PDF)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

Pediatric rheumatology online journal, 2008-09, Vol.6 (S1), p.S26-S26, Article S26

2008

Volltextzugriff (PDF)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Pediatric rheumatology online journal, 2008-09, Vol.6 (S1), p.S2-S2, Article S2

2008

Volltextzugriff (PDF)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)

Pediatric rheumatology online journal, 2008-09, Vol.6 (S1), p.P209-P209, Article P209

2008

Volltextzugriff (PDF)

Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response

Clinical and experimental rheumatology, 1993-09, Vol.11 (5), p.515

1993

Volltextzugriff (PDF)

Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients

The Annals of pharmacotherapy, 2004-10, Vol.38 (10), p.1582-1587

2004

Volltextzugriff (PDF)

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure

The Journal of heart and lung transplantation, 2003-10, Vol.22 (10), p.1117-1125

2003

Volltextzugriff (PDF)

Diffusion of ultra-high energy protons in galaxy clusters and secondary X- and gamma-ray emissions

Astroparticle physics, 2004-11, Vol.22 (2), p.167-181

2004

Volltextzugriff (PDF)

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

Clinical pharmacology and therapeutics, 2001-01, Vol.69 (1), p.48-56

2001

Volltextzugriff (PDF)

Pharmacokinetics of Lumiracoxib in plasma and synovial fluid

Clinical pharmacokinetics, 2004-01, Vol.43 (7), p.467-478

2004

Volltextzugriff (PDF)

Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

Clinical pharmacology and therapeutics, 2001-09, Vol.70 (3), p.247-254

2001

Volltextzugriff (PDF)

Pharmacokinetics of an Everolimus‐Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

American journal of transplantation, 2003-05, Vol.3 (5), p.606-613

2003

Volltextzugriff (PDF)

Differential Influence of Two Cyclosporine Formulations on Everolimus Pharmacokinetics: A Clinically Relevant Pharmacokinetic Interaction

Journal of clinical pharmacology, 2002-01, Vol.42 (1), p.95-99

2002

Volltextzugriff (PDF)

Ärzteausbildung Arlesheim

Der Merkurstab, 2019, Vol.72 (3), p.185-189

2019

Volltextzugriff (PDF)

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Clinical pharmacology and therapeutics, 2001-11, Vol.70 (5), p.425-430

Kovarik, J

2001

Volltextzugriff (PDF)

Effect of rifampin on apparent clearance of everolimus

The Annals of pharmacotherapy, 2002-06, Vol.36 (6), p.981-985

2002

Volltextzugriff (PDF)

Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year

Pediatric transplantation, 2008-06, Vol.12 (4), p.456-463

2008

Volltextzugriff (PDF)

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(188)
Mit Volltextzugriff
(202)

Publikationsform

Artikel
(210)
Reviews
(39)
Bücher
(2)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Revue De Théologie Et De Philosophie
(44)
European Heart Journal
(15)
Europace
(10)
Agents And Actions
(7)
Annals Of Oncology
(7)
Augustinianum
(7)
Journal Of Clinical Pharmacology
(6)
Neurosurgery
(5)
Stroke
(5)
American Journal Of Neuroradiology : Ajnr
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects

Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low-Dose Aspirin in Healthy Subjects

Sotrastaurin and everolimus pharmacokinetics after single-dose coadministration

Clinical pharmacology of lumiracoxib : A selective cyclo-oxygenase-2 inhibitor

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor

Increased interleukin-1 beta (IL-1β) concentration in gingival tissue from periodontitis patients

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)

Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response

Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure

Diffusion of ultra-high energy protons in galaxy clusters and secondary X- and gamma-ray emissions

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine

Pharmacokinetics of Lumiracoxib in plasma and synovial fluid

Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications

Pharmacokinetics of an Everolimus‐Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

Differential Influence of Two Cyclosporine Formulations on Everolimus Pharmacokinetics: A Clinically Relevant Pharmacokinetic Interaction

Ärzteausbildung Arlesheim

Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment

Effect of rifampin on apparent clearance of everolimus

Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year

Suchergebnisse filtern